{"id":11174,"date":"2025-10-02T14:50:09","date_gmt":"2025-10-02T14:50:09","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/?p=11174"},"modified":"2025-10-02T19:33:33","modified_gmt":"2025-10-02T19:33:33","slug":"hiperterminin-faz-iii-calismalarinin","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/tr\/hiperterminin-faz-iii-calismalarinin\/","title":{"rendered":"Modern Onkolojide Hiperterminin Terap\u00f6tik Entegrasyonu: Faz III \u00c7al\u0131\u015fmalar\u0131n\u0131n ve Meta-Analizlerin Ele\u015ftirel Bir Analizi (OS, DFS, CR U\u00e7 Noktalar\u0131)"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Modern Onkolojide Hiperterminin Terap\u00f6tik Entegrasyonu: Faz III \u00c7al\u0131\u015fmalar\u0131n\u0131n ve Meta-Analizlerin Ele\u015ftirel Bir Analizi (OS, DFS, CR U\u00e7 Noktalar\u0131)\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Andromedichyperthermia Center\"\n        }\n      },\n      \"keywords\": \"Hipertermi, Onkoloji, Faz III \u00c7al\u0131\u015fmalar\u0131, Sa\u011fkal\u0131m, OS, Tam Yan\u0131t, CR, Sarkom, Serviks Kanseri, E-E-A-T\"\n      \/* ... Schema FAQPage would be added separately for the FAQ section *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong>Yetki ve Uzmanl\u0131k (E-E-A-T):<\/strong><br \/>\n<strong><a href=\"https:\/\/andromedichyperthermia.com\/tr\/doctor-veronica-iatan\/\">Dr. Veronica Iatan<\/a>, MD, ve <a href=\"https:\/\/andromedichyperthermia.com\/tr\/cristian-gologan\/\">Cristian Gologan M.Sc<\/a>, Andromedichyperthermia<\/strong><\/div>\n<h1>Modern Onkolojide Hiperterminin Terap\u00f6tik Entegrasyonu: Faz III \u00c7al\u0131\u015fmalar\u0131n\u0131n ve Meta-Analizlerin Ele\u015ftirel Bir Analizi (OS, DFS, CR U\u00e7 Noktalar\u0131)<\/h1>\n<h2>1. Y\u00f6netici \u00d6zeti ve Hipertermi&#8217;nin Temel Prensipleri (HT)<\/h2>\n<p>*Onkolojik Hipertermi (HT), kontroll\u00fc olarak **39\u00b0C ile 45\u00b0C* aras\u0131ndaki s\u0131cakl\u0131k aral\u0131\u011f\u0131nda \u0131s\u0131 uygulanmas\u0131 olarak tan\u0131mlan\u0131r ve bir dizi ilerlemi\u015f ve tekrarlayan solid t\u00fcm\u00f6r i\u00e7in *D\u00fczey 1A kan\u0131tlar\u0131yla* (*rastgele Faz III \u00e7al\u0131\u015fmalar\u0131 ve meta-analizler) do\u011frulanm\u0131\u015f **\u00f6nemli bir klinik fayda* g\u00f6steren adjuvan bir tedavi y\u00f6ntemidir.<\/p>\n<div class=\"key-points\">\n<h3>Temel Bulgular &#8211; D\u00fczey 1A Kan\u0131tlar\u0131:<\/h3>\n<ul>\n<li>*Rol\u00fc:* HT, t\u00fcm\u00f6r\u00fc do\u011frudan yok etmez; g\u00fc\u00e7l\u00fc bir *biyolojik hassasla\u015ft\u0131r\u0131c\u0131* olarak hareket eder.<\/li>\n<li>*Do\u011frulanm\u0131\u015f Faydalar:* D\u00fczey 1A kan\u0131tlar\u0131n\u0131n sentezi, *Genel Sa\u011fkal\u0131m (OS)* ve *Tam Yan\u0131t Oran\u0131nda (CR)* tutarl\u0131 bir iyile\u015fme oldu\u011funu vurgular.<\/li>\n<li>*Ba\u015fl\u0131ca Endikasyonlar:* Yumu\u015fak doku sarkomlar\u0131, serviks kanseri, tekrarlayan meme kanseri, malign melanom, mesane kanseri, rektum kanseri ve ba\u015f-boyun t\u00fcm\u00f6rleri (HNC).<\/li>\n<li>*G\u00fcvenlik:* Bu g\u00fc\u00e7l\u00fc terap\u00f6tik fayda, *sistemik toksisitede veya ciddi (grade 3 veya 4) yan etkilerde anlaml\u0131 bir art\u0131\u015f olmadan* s\u00fcrekli olarak elde edilir.<\/li>\n<li>*Sonu\u00e7:* HT, se\u00e7ilmi\u015f t\u00fcm\u00f6rler i\u00e7in standart multimodal tedavilere vazge\u00e7ilmez bir ektir.<\/li>\n<\/ul>\n<\/div>\n<h3>1.1. Onkolojik Hiperterminin S\u0131n\u0131fland\u0131r\u0131lmas\u0131 ve Y\u00f6ntemleri<\/h3>\n<h4>1.1.1. Loko-b\u00f6lgesel Hipertermi (L-R HT)<\/h4>\n<p>Bu y\u00f6ntem, pelvik, torasik ve abdominal t\u00fcm\u00f6rlerin derin \u0131s\u0131t\u0131lmas\u0131 i\u00e7in kullan\u0131l\u0131r. Ama\u00e7, sa\u011fl\u0131kl\u0131 dokular\u0131 tolerans s\u0131n\u0131rlar\u0131 i\u00e7inde tutarken, t\u00fcm\u00f6r hacminde terap\u00f6tik s\u0131cakl\u0131klara ula\u015fmak i\u00e7in termal enerjiyi derinli\u011fe y\u00f6nlendirmektir. T\u00fcm\u00f6r k\u00fctlesinin m\u00fcmk\u00fcn oldu\u011funca homojen (izotermal) \u0131s\u0131t\u0131lmas\u0131 hedeflenir.<\/p>\n<h4>1.1.2. RF-Mod\u00fcle Edilmi\u015f Hipertermi (mHT)<\/h4>\n<p>Mod\u00fcle edilmi\u015f RF hipertermi (mHT), geleneksel izotermal \u0131s\u0131tman\u0131n aksine, zamansal fraktal dalgalanmalarla mod\u00fcle edilmi\u015f kapasitif bir e\u015fle\u015fme kullan\u0131r. \u00c7al\u0131\u015fma prensibi, *h\u00fccre zar\u0131 d\u00fczeyinde odaklanm\u0131\u015f enerji transferine* dayan\u0131r. Y\u00fcksek dielektrik kay\u0131p, tercihen kanserli h\u00fccre zarlar\u0131nda meydana gelir ve apoptoz yollar\u0131n\u0131 uyaran spesifik bir s\u0131cakl\u0131k gradyan\u0131 olu\u015fturur. Bu &#8220;i\u00e7ten d\u0131\u015fa&#8221; \u0131s\u0131tma mekanizmas\u0131, daha y\u00fcksek t\u00fcm\u00f6r i\u00e7i s\u0131cakl\u0131klar ve normal doku \u00fczerinde azalm\u0131\u015f hasar ile sonu\u00e7lan\u0131r.<\/p>\n<h4>1.1.3. \u0130nterstisyel Hipertermi<\/h4>\n<p>Bu y\u00f6ntem, \u0131s\u0131y\u0131 do\u011frudan t\u00fcm\u00f6r i\u00e7ine yerle\u015ftirilen antenler, \u00e7ubuklar veya tohumlar arac\u0131l\u0131\u011f\u0131yla invaziv olarak iletir. Genellikle beyin t\u00fcm\u00f6rleri (gliomlar) veya tekrarlayan y\u00fczeyel lezyonlar i\u00e7in kullan\u0131l\u0131r.<\/p>\n<h3>1.2. 39\u201345 \u00b0C Terap\u00f6tik Pencere Neden \u00c7al\u0131\u015f\u0131r? (Biyolojik Mekanizmalar)<\/h3>\n<p>HT&#8217;nin Faz III d\u00fczeyindeki klinik etkinli\u011fi, karma\u015f\u0131k biyolojik mekanizmalar\u0131n\u0131n anla\u015f\u0131lmas\u0131na ayr\u0131lmaz bir \u015fekilde ba\u011fl\u0131d\u0131r. Bu mekanizmalar, basit h\u00fccresel y\u0131k\u0131m\u0131 a\u015far ve HT&#8217;yi standart tedavilerin *\u00e7ok i\u015flevli bir hassasla\u015ft\u0131r\u0131c\u0131s\u0131* olarak konumland\u0131r\u0131r. Optimal s\u0131cakl\u0131k olan *39\u201345 \u00b0C*, t\u00fcm\u00f6re \u00f6zg\u00fc h\u00fccresel dengesizlikleri maksimize etmek i\u00e7in se\u00e7ilmi\u015ftir. Randomize \u00e7al\u0131\u015fmalarda g\u00f6zlemlenen genel ba\u015far\u0131, t\u00fcm\u00f6r mikro\u00e7evresi ve h\u00fccresel makine ile etkile\u015fime girerek radyoterapi (RT) ve kemoterapinin (CHT) etkinli\u011fini art\u0131ran bu hassasla\u015ft\u0131rma rol\u00fcnden kaynaklanmaktad\u0131r.<\/p>\n<hr \/>\n<h2>2. Etki Mekanizmalar\u0131: Hipertermi, Onkolojik Tedaviyi Nas\u0131l G\u00fc\u00e7lendirir?<\/h2>\n<p>Kombine tedavinin \u00fcst\u00fcn klinik etkinli\u011fi, t\u00fcm\u00f6r direncini birden fazla d\u00fczeyde hedefleyen g\u00fc\u00e7l\u00fc bir biyolojik sinerjinin sonucudur.<\/p>\n<h3>2.1. Radyosensitivizasyon: T\u00fcm\u00f6r Direncini ve DNA Onar\u0131m\u0131n\u0131 A\u015fma<\/h3>\n<p>Hipertermi, radyoterapinin en \u00f6nemli iki ba\u015far\u0131s\u0131zl\u0131k nedenini ele alan g\u00fc\u00e7l\u00fc bir radyosensitivizat\u00f6r olarak kabul edilir:<\/p>\n<ol>\n<li>*DNA Onar\u0131m\u0131n\u0131n \u0130nhibisyonu:* HT, radyasyonun zarar verdi\u011fi DNA onar\u0131m mekanizmalar\u0131n\u0131 engeller, daha etkili ve geri d\u00f6nd\u00fcr\u00fclemez bir h\u00fccre \u00f6l\u00fcm\u00fcn\u00fc sa\u011flar.<\/li>\n<li>*Mikro\u00e7evrenin Oksijenlenmesi:* HT, kan ak\u0131\u015f\u0131n\u0131 art\u0131r\u0131r ve t\u00fcm\u00f6r oksijenlenmesini iyile\u015ftirir, hipoksik (radyasyona diren\u00e7li) fraksiyonu azalt\u0131r.<\/li>\n<\/ol>\n<p>T\u00fcm\u00f6r mikro\u00e7evresindeki bu i\u015flevsel de\u011fi\u015fiklik, daha \u00f6nce diren\u00e7li olan kanser h\u00fccrelerinin geleneksel \u0131\u015f\u0131nlamaya \u00e7ok daha duyarl\u0131 hale gelmesini sa\u011flar. Bu, *lokal olarak ilerlemi\u015f serviks kanseri (LACC) ve ba\u015f-boyun t\u00fcm\u00f6rleri (HNC)* gibi t\u00fcm\u00f6rler i\u00e7in hipertermi ile kemoradyoterapi (CCRT+HT) rejimlerinde belgelenmi\u015f y\u00fcksek loko-b\u00f6lgesel kontrol ve CR oranlar\u0131n\u0131n alt\u0131nda yatan kilit bir fakt\u00f6rd\u00fcr.<\/p>\n<h3>2.2. Kemohassasiyet: \u0130la\u00e7 Trafi\u011fini ve H\u00fccresel Emilimini \u0130yile\u015ftirme<\/h3>\n<h4>2.2.1. Temel Ajanlarla Sinerji ve Katk\u0131<\/h4>\n<p>HT, belirli temel onkolojik kemoterapi s\u0131n\u0131flar\u0131yla g\u00fc\u00e7l\u00fc sinerjik etkiler g\u00f6sterir. \u00d6zellikle, HT, platin bazl\u0131 ajanlar (sisplatin, karboplatin) ve mitomisin C ile sinerjik olarak hareket eder. Ayr\u0131ca, doksorubisin, siklofosfamid ve gemsitabin gibi ajanlarla da katk\u0131sal etkilere sahiptir.<\/p>\n<h4>2.2.2. Farmakokinetik Amplifikasyon<\/h4>\n<p>HT, t\u00fcm\u00f6rlerde ve lenf d\u00fc\u011f\u00fcmlerinde (LN) ila\u00e7 trafi\u011fini art\u0131rarak ila\u00e7lar\u0131n t\u00fcm\u00f6r d\u00fczeyinde teslimat\u0131n\u0131 optimize eder. mHT durumunda, h\u00fccre zar\u0131 d\u00fczeyindeki lokalize \u0131s\u0131tma mekanizmas\u0131, kemoterap\u00f6tik ajanlar\u0131n h\u00fccre i\u00e7i emilimini art\u0131rabilir.<\/p>\n<h3>2.3. \u0130mm\u00fcnomod\u00fclasyon: &#8220;So\u011fuk&#8221; Bir T\u00fcm\u00f6r\u00fc &#8220;S\u0131cak&#8221; (\u0130mm\u00fcnojenik) Bir T\u00fcm\u00f6re D\u00f6n\u00fc\u015ft\u00fcrme<\/h3>\n<p>HT&#8217;nin, antit\u00fcm\u00f6r imm\u00fcn yan\u0131t\u0131 mod\u00fcle etme, etkili bir \u015fekilde imm\u00fcnolojik olarak *&#8221;so\u011fuk&#8221; t\u00fcm\u00f6rleri &#8220;s\u0131cak&#8221;* (iltihapl\u0131) t\u00fcm\u00f6rlere d\u00f6n\u00fc\u015ft\u00fcrme yetene\u011fi, giderek daha fazla kabul g\u00f6ren bir etki mekanizmas\u0131d\u0131r. HT, Is\u0131 \u015eoku Proteinleri (HSP) ve t\u00fcm\u00f6r antijenlerinin sal\u0131n\u0131m\u0131n\u0131 ind\u00fckleyerek bir *&#8221;yerinde t\u00fcm\u00f6r a\u015f\u0131s\u0131&#8221;* olarak hareket eder. HSP&#8217;ler (HSP70 gibi), tehlike sinyalleri olarak hareket eder ve antijenlerin dendritik h\u00fccreler (DC) taraf\u0131ndan al\u0131nmas\u0131n\u0131 kolayla\u015ft\u0131r\u0131r. Bu imm\u00fcnomod\u00fclat\u00f6r s\u00fcre\u00e7, Do\u011fal Katil (NK) h\u00fccreleri ve CD8+ T lenfositleri taraf\u0131ndan artan t\u00fcm\u00f6r h\u00fccresi lizisine yol a\u00e7ar. Ayr\u0131ca, HT, h\u00fccresel yap\u0131\u015fma molek\u00fcllerinin (CAM) ekspresyonunu iyile\u015ftirir, lenfositlerin t\u00fcm\u00f6r b\u00f6lgesine hareketini kolayla\u015ft\u0131r\u0131r.<\/p>\n<p>*Tablo 1, hiperterminin standart onkolojik tedavilerle mekanik etkile\u015fimlerini \u00f6zetlemektedir.*<\/p>\n<p>*Tablo 1: Hiperterminin Standart Onkolojik Terapilerle Etkile\u015fim Mekanizmalar\u0131*<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Hedef Mekanizma<\/strong><\/td>\n<td width=\"104\"><strong>Biyolojik Etki (39 \u00b0C &#8211; 45 \u00b0C)<\/strong><\/td>\n<td width=\"104\"><strong>Terap\u00f6tik Sinerji<\/strong><\/td>\n<td width=\"104\"><strong>Sinerjik Ajanlar<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">DNA Onar\u0131m\u0131n\u0131n \u0130nhibisyonu<\/td>\n<td width=\"104\">DNA onar\u0131m mekanizmalar\u0131n\u0131 engeller;<\/td>\n<td width=\"104\">S faz\u0131ndaki h\u00fccreleri hassasla\u015ft\u0131r\u0131r<br \/>\nG\u00fc\u00e7l\u00fc Radyosensitivizat\u00f6r (RT&#8217;yi tamamlar)<\/td>\n<td width=\"104\">Radyoterapi (RT)<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">T\u00fcm\u00f6r Mikro\u00e7evresi<\/td>\n<td width=\"104\">Kan ak\u0131\u015f\u0131n\u0131 art\u0131r\u0131r, t\u00fcm\u00f6r oksijenlenmesini iyile\u015ftirir, vask\u00fclarizasyonu art\u0131r\u0131r<\/td>\n<td width=\"104\">RT&#8217;nin etkinli\u011fini art\u0131r\u0131r; \u0130la\u00e7 trafi\u011fini iyile\u015ftirir (Kemohassasiyet)<\/td>\n<td width=\"104\">RT, Sisplatin, Mitomisin C<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">H\u00fccre Zar\u0131\/Yap\u0131s\u0131<\/td>\n<td width=\"104\">Artan dielektrik kay\u0131p;<br \/>\nDo\u011frudan apoptotik sinyalizasyon<\/td>\n<td width=\"104\">\u0130la\u00e7 emilimini iyile\u015ftirir;<\/td>\n<td width=\"104\">Sisplatin, Karboplatin, Bleomisin<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Ba\u011f\u0131\u015f\u0131kl\u0131k Sistemi<\/td>\n<td width=\"104\">HSP&#8217;lerin sal\u0131n\u0131m\u0131, DC aktivasyonu, T h\u00fccrelerinin haz\u0131rlanmas\u0131, NK\/CD8+-T h\u00fccreleri taraf\u0131ndan lizisin yukar\u0131 reg\u00fclasyonu<\/td>\n<td width=\"104\">T\u00fcm\u00f6r \u0130mm\u00fcnomod\u00fclat\u00f6r\u00fc; Artan Antit\u00fcm\u00f6r Ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131<\/td>\n<td width=\"104\">\u0130mm\u00fcnoterapi, RT, CHT<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<figure id=\"attachment_11120\" aria-describedby=\"caption-attachment-11120\" style=\"width: 747px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11120 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie.jpg\" alt=\"Hiperterminin Biyolojik Mekanizmalar\u0131\" width=\"747\" height=\"412\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie.jpg 747w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie-300x165.jpg 300w\" sizes=\"auto, (max-width: 747px) 100vw, 747px\" \/><figcaption id=\"caption-attachment-11120\" class=\"wp-caption-text\">Hiperterminin Biyolojik Mekanizmalar\u0131<\/figcaption><\/figure>\n<h2>3. D\u00fczey 1A Kan\u0131tlar\u0131n\u0131n Sentezi: Meta-Analizler ve Toplu Veri Sonu\u00e7lar\u0131<\/h2>\n<p>HT&#8217;nin sa\u011flam de\u011ferlendirmesi, Faz III \u00e7al\u0131\u015fmalar\u0131n\u0131n toplu analizine dayanmaktad\u0131r. *D\u00fczey 1A kan\u0131tlar\u0131n\u0131n sentezi, HT&#8217;nin standart tedaviye eklenmesinin \u00e7e\u015fitli t\u00fcm\u00f6r kategorilerinde genelle\u015ftirilmi\u015f bir klinik fayda sa\u011flad\u0131\u011f\u0131n\u0131 do\u011frulamaktad\u0131r.*<\/p>\n<h3>3.1. Meta-Analitik Sonu\u00e7lara Genel Bak\u0131\u015f<\/h3>\n<p>*HT&#8217;nin etkinli\u011fine ili\u015fkin yak\u0131n tarihli bir analiz, alt\u0131 loko-b\u00f6lgesel HT \u00e7al\u0131\u015fmas\u0131n\u0131n be\u015finin, HT&#8217;nin standart kemo- ve\/veya radyoterapiye eklenmesiyle artan Genel Sa\u011fkal\u0131m (OS) ve\/veya iyile\u015ftirilmi\u015f Tam Yan\u0131t Oran\u0131 (CR) g\u00f6sterdi\u011fini tespit etmi\u015ftir [2]. Bu, HT&#8217;nin \u00e7ok \u00e7e\u015fitli loko-b\u00f6lgesel t\u00fcm\u00f6r lokalizasyonlar\u0131 i\u00e7in D\u00fczey 1A adjuvan olarak kullan\u0131m\u0131n\u0131 destekleyen sa\u011flam bir bilimsel fikir birli\u011fi olu\u015fturmaktad\u0131r.*<\/p>\n<h3>3.2. \u00d6l\u00e7\u00fclebilir Kazan\u00e7lar: Genel Sa\u011fkal\u0131m (OS), Tam Yan\u0131t (CR) ve Lokal Kontrol<\/h3>\n<p>HT&#8217;nin klinik faydalar\u0131, kritik onkolojik u\u00e7 noktalarda \u00f6l\u00e7\u00fclebilirdir. *Lokal Olarak \u0130lerlemi\u015f Serviks Kanseri (LACC)* i\u00e7in toplu veriler \u015funlar\u0131 g\u00f6stermektedir:<\/p>\n<ul>\n<li>*Tam Yan\u0131t (CR):* HT&#8217;nin eklenmesiyle CR oran\u0131 anlaml\u0131 \u00f6l\u00e7\u00fcde artar (Ba\u011f\u0131l Risk \u2013 *RR 0.56, %95 CI 0.39 ila 0.79; **p &lt; 0.001*).<\/li>\n<li>*Lokal N\u00fcks Kontrol\u00fc:* HT, lokal n\u00fcks oran\u0131n\u0131 anlaml\u0131 \u00f6l\u00e7\u00fcde azalt\u0131r (Risk Oran\u0131 \u2013 *HR 0.48, %95 CI 0.37 ila 0.63; **p &lt; 0.001*).<\/li>\n<li>*Genel Sa\u011fkal\u0131m (OS):* HT ile multimodal tedavi, daha iyi bir OS&#8217;ye yol a\u00e7ar (HR *0.67, %95 CI 0.45 ila 0.99; **p = 0.05*).<\/li>\n<\/ul>\n<h2><\/h2>\n<h2>4. Kansere \u00d6zg\u00fc Faz III \u00c7al\u0131\u015fmalar\u0131n\u0131n Analizi<\/h2>\n<p>Bu ayr\u0131nt\u0131l\u0131 analiz, *HT&#8217;nin en y\u00fcksek kalibreli rastgele klinik \u00e7al\u0131\u015fmalarla desteklendi\u011fi t\u00fcm\u00f6r lokalizasyonlar\u0131n\u0131 incelemekte, ana sa\u011fkal\u0131m ve yan\u0131t sonu\u00e7lar\u0131na odaklanmaktad\u0131r*.<\/p>\n<h3><\/h3>\n<h3>4.1. Yumu\u015fak Doku Sarkomlar\u0131 (YDS)<\/h3>\n<p>Yumu\u015fak doku sarkomu, HT entegrasyonu i\u00e7in Faz III \u00e7al\u0131\u015fmalar\u0131yla desteklenen model endikasyonlardan biridir. Standart neoadjuvan kemoterapiyi, b\u00f6lgesel hipertermi (RHT) art\u0131 neoadjuvan kemoterapi ile kar\u015f\u0131la\u015ft\u0131ran \u00e7al\u0131\u015fmalar, *HT&#8217;nin eklenmesinin artan sa\u011fkal\u0131ma ve iyile\u015fmi\u015f lokal ilerlemesiz sa\u011fkal\u0131ma (LPFS) yol a\u00e7t\u0131\u011f\u0131n\u0131* g\u00f6stermi\u015ftir.<br \/>\nAyr\u0131ca, bu \u00e7al\u0131\u015fmalar\u0131n \u00e7evirisel bir analizi, RHT ile kombine preoperatif tedavinin, t\u00fcm\u00f6r\u00fc temel olarak inflamatuar olmayan bir durumdan inflamatuar bir duruma d\u00f6n\u00fc\u015ft\u00fcrd\u00fc\u011f\u00fcn\u00fc ortaya \u00e7\u0131kard\u0131. Bu t\u00fcm\u00f6r mikro\u00e7evresi yeniden programlamas\u0131, artan antit\u00fcm\u00f6r imm\u00fcn aktiviteye olanak tan\u0131r.<\/p>\n<h3>4.2. Jinekolojik Kanserler: Lokal Olarak \u0130lerlemi\u015f Serviks Kanseri (LACC)<\/h3>\n<p>LACC&#8217;deki HT kan\u0131t\u0131, onkolojideki en ikna edici kan\u0131tlar aras\u0131ndad\u0131r ve e\u015f zamanl\u0131 kemoradyoterapiye (CCRT) bir ek olarak kullan\u0131lmas\u0131n\u0131 destekler.<\/p>\n<h4>4.2.1. \u00c7al\u0131\u015fmalar\u0131n Uzla\u015f\u0131s\u0131 (CR ve Lokal N\u00fcks)<\/h4>\n<p>Meta-analizler ve randomize \u00e7al\u0131\u015fmalardan elde edilen toplu veriler, \u00fc\u00e7 modlu tedavinin (CCRT + HT) faydas\u0131n\u0131 sistematik olarak do\u011frulamaktad\u0131r. *Toplu verilerin analizi, kombine tedavi ile anlaml\u0131 \u00f6l\u00e7\u00fcde daha y\u00fcksek bir Tam Yan\u0131t Oran\u0131 (CR) (RR 0.56; p &lt; 0.001) ve daha d\u00fc\u015f\u00fck bir lokal n\u00fcks oran\u0131 (HR 0.48; p &lt; 0.001) g\u00f6stermi\u015ftir. Bu m\u00fckemmel loko-b\u00f6lgesel kontrol, \u00fc\u00e7 modlu tedaviyi uygulanabilir ve etkili bir yakla\u015f\u0131m haline getirmi\u015ftir.*<\/p>\n<h4>4.2.2. Genel Sa\u011fkal\u0131m\u0131n Nicelendirilmesi (OS)<\/h4>\n<p>*Genel Sa\u011fkal\u0131m (OS), CCRT&#8217;nin HT ile ili\u015fkilendirilmesiyle anlaml\u0131 \u00f6l\u00e7\u00fcde iyile\u015fmi\u015ftir (HR 0.67, %95 CI 0.45 ila 0.99; p = 0.05).*<br \/>\nO d\u00f6nemin N3 skuam\u00f6z servikal lenf d\u00fc\u011f\u00fcmleri i\u00e7in RT +- HT&#8217;yi de\u011ferlendiren \u0130talya&#8217;dan bir Faz III \u00e7al\u0131\u015fmas\u0131 \u00e7arp\u0131c\u0131 bir fark g\u00f6sterdi: *Kombine tedavi grubundaki CR oran\u0131 %82.3* iken, sadece radyoterapi ile tedavi edilen onkoloji hastalar\u0131nda *%36.8* idi [3,4]. Ayn\u0131 \u00e7al\u0131\u015fman\u0131n uzun vadeli analizi, hipertermi kolunda *5 y\u0131ll\u0131k Genel Sa\u011fkal\u0131m\u0131 %55* olarak bildirirken, sadece radyoterapi kolunda *%0* olarak rapor etti [3,4].<\/p>\n<h4>4.2.3. Ek Kan\u0131tlar (OS)<\/h4>\n<p>En g\u00fc\u00e7l\u00fc ek kan\u0131t d\u00fczeyi, loko-b\u00f6lgesel Hiperterminin Radyoterapi (RT) veya Kemoradyoterapi (CTRT) ile birle\u015ftirildi\u011fi \u00e7ok say\u0131da randomize \u00e7al\u0131\u015fmada incelenen *Serviks Kanserinden* gelmektedir.<\/p>\n<p>Bu sonu\u00e7lar (serviks kanseri i\u00e7in D\u00fczey 1A kan\u0131tlar\u0131), standart tedaviyi (RT veya CTRT) kombine tedavi (RT\/CTRT + Hipertermi) ile kar\u015f\u0131la\u015ft\u0131ran meta-analizlerden elde edilmi\u015ftir:<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"208\">Klinik G\u00f6sterge<\/td>\n<td width=\"208\">RT + Hipertermi ile Elde Edilen Sonu\u00e7<\/td>\n<td width=\"208\">Referans (Akran De\u011ferlendirmeli Al\u0131nt\u0131lar)<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"208\"><strong>Tam Yan\u0131t (CR)<\/strong><\/td>\n<td width=\"208\">CR oran\u0131nda tutarl\u0131 iyile\u015fme: Sadece RT&#8217;ye k\u0131yasla <strong>+%22.1<\/strong>.<\/td>\n<td width=\"208\">Meta-analizler<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Loko-b\u00f6lgesel Kontrol (LRC)<\/strong><\/td>\n<td width=\"208\">Anlaml\u0131 iyile\u015fme: Sadece RT&#8217;ye k\u0131yasla <strong>+%23.1<\/strong>.<\/td>\n<td width=\"208\">Meta-analizler<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Genel Sa\u011fkal\u0131m (OS)<\/strong><\/td>\n<td width=\"208\">Hipertermi&#8217;nin eklenmesiyle uzun vadeli OS&#8217;de iyile\u015fme g\u00f6zlemlendi (HR 0.67; p = 0.03).<\/td>\n<td width=\"208\">G\u00fcncellenmi\u015f Meta-analiz<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Hastal\u0131k Olmaks\u0131z\u0131n Sa\u011fkal\u0131m (DFS)<\/strong><\/td>\n<td width=\"208\">CTRT ile kombinasyon halinde 2 ve 3 y\u0131ll\u0131k DFS&#8217;de anlaml\u0131 iyile\u015fme.<\/td>\n<td width=\"208\">Faz III Randomize \u00c7al\u0131\u015fmalar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li>*Ba\u015fl\u0131k:* Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma<\/li>\n<li>*Yazarlar:* Lutgens L, van der Zee J, Pijls-Johannesma M, et al.<\/li>\n<li>*PubMed Ba\u011flant\u0131s\u0131 (2010 G\u00fcncellemesi):* <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20091593\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20091593\/<\/a><\/li>\n<\/ul>\n<h5>4.2.3.2. A\u011f Meta-Analizi (NMA): En \u0130yi Stratejiler (Datta ve ark. 2019)<\/h5>\n<p>Bu \u00e7al\u0131\u015fma, Hipertermi&#8217;yi di\u011fer 13 terap\u00f6tik m\u00fcdahale ile kar\u015f\u0131la\u015ft\u0131rmak i\u00e7in geli\u015fmi\u015f bir y\u00f6ntem (A\u011f Meta-Analizi) kullanm\u0131\u015ft\u0131r.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Do\u011frulanm\u0131\u015f G\u00f6stergeler<\/td>\n<td width=\"312\">Anahtar Sonu\u00e7<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Tedavi S\u0131ralamas\u0131<\/strong><\/td>\n<td width=\"312\"><strong>RT+HT<\/strong> ve <strong>CTRT+HT<\/strong>, LRC, OS ve toksisite \u00fczerinde en iyi kapsaml\u0131 etkiye sahip ilk \u00fc\u00e7 m\u00fcdahale aras\u0131nda yer ald\u0131.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li>*Ba\u015fl\u0131k:* Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials<\/li>\n<li>*Yazarlar:* Datta NR, Stutz E, Gomez S, Bodis S.<\/li>\n<li>*PubMed Ba\u011flant\u0131s\u0131:* <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30391522\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30391522\/<\/a><\/li>\n<\/ul>\n<h5>4.2.3.3. Faz III \u00c7al\u0131\u015fmas\u0131: mEHT ile Hastal\u0131k Olmaks\u0131z\u0131n Sa\u011fkal\u0131m (DFS) ve Ya\u015fam Kalitesi (QoL)<\/h5>\n<p>Bu, Kemoradyoterapiye (CTRT) eklenen modern bir Hipertermi tekni\u011fi (mEHT) ile DFS ve Ya\u015fam Kalitesinde (QoL) iyile\u015fmeler gibi faydalar\u0131 do\u011frulayan daha yeni Faz III \u00e7al\u0131\u015fmalar\u0131ndan biridir.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Do\u011frulanm\u0131\u015f G\u00f6stergeler<\/td>\n<td width=\"312\">Anahtar Sonu\u00e7<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Hastal\u0131k Olmaks\u0131z\u0131n Sa\u011fkal\u0131m (DFS)<\/strong><\/td>\n<td width=\"312\">CTRT&#8217;ye mEHT eklenmesiyle 2 ve 3 y\u0131ll\u0131k DFS&#8217;de anlaml\u0131 iyile\u015fme.<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Ya\u015fam Kalitesi (QoL)<\/strong><\/td>\n<td width=\"312\">Toksisiteyi art\u0131rmadan QoL&#8217;de anlaml\u0131 iyile\u015fme.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li>*Ba\u015fl\u0131k:* Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients<\/li>\n<li>*Yazarlar:* Minnaar CA, Maposa I, Kotzen JA, et al.<\/li>\n<li>*MDPI Ba\u011flant\u0131s\u0131 (Tam Metin Mevcut):* <a href=\"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/656\" target=\"_blank\" rel=\"noopener\">https:\/\/www.mdpi.com\/2072-6694\/14\/3\/656<\/a><\/li>\n<\/ul>\n<p>Lokal olarak ilerlemi\u015f serviks kanseri i\u00e7in, loko-b\u00f6lgesel hipertermi, sadece t\u00fcm\u00f6r\u00fcn yerel olarak yok edilme \u015fans\u0131n\u0131 (CR) art\u0131rmakla kalmaz, ayn\u0131 zamanda uzun vadeli sa\u011fkal\u0131m (OS ve DFS) \u00fczerinde de \u00f6nemli ve olumlu bir etkiye sahiptir.<\/p>\n<h3>4.3. Ba\u015f ve Boyun Kanserleri (HNC)<\/h3>\n<p>Loko-b\u00f6lgesel Hipertermi, n\u00fcksler ve ilerlemi\u015f hastal\u0131k dahil olmak \u00fczere \u00e7e\u015fitli ba\u015f ve boyun t\u00fcm\u00f6rleri i\u00e7in *D\u00fczey 1A* tedavisidir.<\/p>\n<h4>4.3.1. Faz III Randomize \u00c7al\u0131\u015fma Verileri<\/h4>\n<p>*Prospektif, randomize Faz III \u00e7al\u0131\u015fmalar, nazofarenks kanserinde (NPC) kemoradyoterapinin (CRT) HT ile birle\u015ftirilmesinin tek ba\u015f\u0131na CRT&#8217;ye k\u0131yasla a\u00e7\u0131k bir faydas\u0131n\u0131 belgeledi.*<br \/>\n\u25cf *<a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\">Kang 2013<\/a> (NPC):* Bu Faz III \u00e7al\u0131\u015fmas\u0131 anlaml\u0131 bir iyile\u015fme g\u00f6sterdi. *5 y\u0131ll\u0131k Hastal\u0131k Olmaks\u0131z\u0131n Sa\u011fkal\u0131m (DFS) %25.5&#8217;ten %51.3&#8217;e y\u00fckseldi (p &lt; 0.005)* ve *5 y\u0131ll\u0131k OS %50&#8217;den %68.4&#8217;e y\u00fckseldi (p &lt; 0.005)*. CR oran\u0131 da %62.8&#8217;den %81.6&#8217;ya y\u00fckseldi.<br \/>\n\u25cf *<a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\">Huilgol 2010<\/a> (Oral Kavite\/Orofarinks\/Hipofarinks):* Tam yan\u0131t, sadece radyoterapi ile tedavi edilen grupta *%42.4* iken, HT ile tedavi edilen grupta *%78.6* olarak g\u00f6zlendi. Fark istatistiksel olarak anlaml\u0131yd\u0131 (&lt; 0.05).<br \/>\nHNC&#8217;de DFS ve OS&#8217;deki \u00f6nemli ve tutarl\u0131 kazan\u00e7lar, HT&#8217;nin lokal radyorezistans\u0131 yenmede etkili oldu\u011funu ve iyile\u015fme ama\u00e7l\u0131 tedavinin \u00f6nemli bir bile\u015feni haline geldi\u011fini vurgulamaktad\u0131r [5].<\/p>\n<h3>4.4. Gastrointestinal Kanserler: Rektal ve Anal Kanser<\/h3>\n<p>Lokal olarak ilerlemi\u015f rektal kanserde HT&#8217;nin neoadjuvan kemoradyoterapi (CRT) ile entegrasyonu, loko-b\u00f6lgesel kontrol ve sa\u011fkal\u0131mda kritik faydalar g\u00f6sterdi.<\/p>\n<h4>4.4.1. Rektal Kanser Faz III Sonu\u00e7lar\u0131<\/h4>\n<p>*<a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">Ott 2019<\/a>* prospektif randomize \u00e7al\u0131\u015fmas\u0131, CRT&#8217;yi CRT + HT ile kar\u015f\u0131la\u015ft\u0131rd\u0131 ve HT kolunda 5 y\u0131lda \u00f6nemli iyile\u015fmeler bildirdi:<br \/>\n*\u25cf Genel Sa\u011fkal\u0131m (OS): %95.8&#8217;e kar\u015f\u0131 %74.5 (P = 0.045).*<br \/>\n*\u25cf Hastal\u0131k Olmaks\u0131z\u0131n Sa\u011fkal\u0131m (DFS): %89.1&#8217;e kar\u015f\u0131 %70.4 (P = 0.027).*<br \/>\n*\u25cf Lokal N\u00fckss\u00fcz Sa\u011fkal\u0131m (LRFS): %97.7&#8217;ye kar\u015f\u0131 %78.7 (P = 0.006).*<\/p>\n<h4>4.4.2. Patolojik Yan\u0131t ve Klinik \u0130mplikasyonlar<\/h4>\n<p>Patolojik Tam Yan\u0131t Oran\u0131 (pCR) da HT&#8217;nin eklenmesiyle iyile\u015fmi\u015ftir, *bir meta-analiz %16&#8217;dan (CRT) %22.5&#8217;e (CRT+HT, p = 0.043) bir art\u0131\u015f g\u00f6stermi\u015ftir.*<br \/>\n*\u00d6zellikle, \u00fcst\u00fcn LRFS oran\u0131 (%97.7) ve kolostomisiz sa\u011fkal\u0131m oranlar\u0131ndaki iyile\u015fme (%87.7&#8217;ye kar\u015f\u0131 %69.0, P = 0.016), HT&#8217;nin sadece lokal t\u00fcm\u00f6r sterilizasyonundaki de\u011fil, ayn\u0131 zamanda sfinkter koruma stratejilerindeki rol\u00fcn\u00fc de vurgulamaktad\u0131r.*<\/p>\n<p>&nbsp;<\/p>\n<h3>4.5. Malign Melanom (Loko-b\u00f6lgesel Hastal\u0131k)<\/h3>\n<p>*Temel Faz III ara\u015ft\u0131rmalar\u0131 (<a href=\"https:\/\/pubmed.ncbi.nlm.nihs.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\">Overgaard ve ark., 1995<\/a>), radyoterapinin HT ile ili\u015fkilendirilmesinin ilerlemi\u015f melanomda Tam Yan\u0131t Oran\u0131n\u0131 ve OS&#8217;yi iyile\u015ftirdi\u011fini g\u00f6stermi\u015ftir.*<\/p>\n<p>*Anahtar Sonu\u00e7lar: RT + Hipertermi vs. Radyoterapi*<\/p>\n<p>Avrupa \u00e7ok merkezli \u00e7al\u0131\u015fmas\u0131, 70 hastadaki 134 metastatik veya tekrarlayan melanom lezyonunu, ya sadece radyoterapi ya da radyoterapiyi takiben hipertermi (43\u00b0C, 60 dakika boyunca) alacak \u015fekilde rastgele atad\u0131.<\/p>\n<h5>1. Lokal T\u00fcm\u00f6r Kontrol\u00fc (Birincil U\u00e7 Nokta)<\/h5>\n<p>En \u00f6nemli sonu\u00e7, uzun vadeli lokal t\u00fcm\u00f6r kontrol\u00fcnde anlaml\u0131 bir iyile\u015fme oldu.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"156\">G\u00f6sterge<\/td>\n<td width=\"156\">Sadece Radyoterapi (RT)<\/td>\n<td width=\"156\">Radyoterapi + Hipertermi (RT + HT)<\/td>\n<td width=\"156\">Anahtar Fark<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"156\"><strong>2 Y\u0131l Akt\u00fceryal Lokal Kontrol<\/strong><\/td>\n<td width=\"156\"><strong>%28<\/strong><\/td>\n<td width=\"156\"><strong>%46<\/strong><\/td>\n<td width=\"156\"><strong>Anlaml\u0131 iyile\u015fme (p = 0.008)<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li>*Sonu\u00e7:* HT&#8217;nin eklenmesi, 2 y\u0131lda lokal t\u00fcm\u00f6r kontrol\u00fcn\u00fc *18 y\u00fczde puan\u0131* art\u0131rd\u0131.<\/li>\n<\/ul>\n<h5>2. \u00c7ok De\u011fi\u015fkenli Analiz (Prognostik Fakt\u00f6rler)<\/h5>\n<p>Cox \u00e7ok de\u011fi\u015fkenli regresyon analizi, *hiperterminin* 2 y\u0131ll\u0131k lokal kontrol i\u00e7in en \u00f6nemli prognostik fakt\u00f6r oldu\u011funu do\u011frulad\u0131.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"208\">Prognostik De\u011fi\u015fken<\/td>\n<td width=\"208\">Risk (Olas\u0131l\u0131k Oran\u0131)<\/td>\n<td width=\"208\">P De\u011feri<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"208\"><strong>Hipertermi<\/strong><\/td>\n<td width=\"208\"><strong>1.73<\/strong> (lokal kontrol i\u00e7in)<\/td>\n<td width=\"208\"><strong>p = 0.023<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"208\">Radyasyon Dozu<\/td>\n<td width=\"208\">1.17<\/td>\n<td width=\"208\">p = 0.05<\/td>\n<\/tr>\n<tr>\n<td width=\"208\">T\u00fcm\u00f6r Boyutu<\/td>\n<td width=\"208\">0.91<\/td>\n<td width=\"208\">p = 0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li>*Sonu\u00e7:* Bu, HT&#8217;nin sa\u011flad\u0131\u011f\u0131 faydan\u0131n ba\u011f\u0131ms\u0131z oldu\u011funu ve uygulanan radyasyon dozu ve t\u00fcm\u00f6r boyutu kadar \u00f6nemli oldu\u011funu g\u00f6stermektedir.<\/li>\n<\/ul>\n<h5>3. Sa\u011fkal\u0131m (Lokal Kontrol \u0130yile\u015ftiricidir)<\/h5>\n<p>\u00c7al\u0131\u015fma, ba\u015far\u0131l\u0131 lokal kontrol ile uzun vadeli sa\u011fkal\u0131m aras\u0131nda g\u00fc\u00e7l\u00fc bir ba\u011flant\u0131 g\u00f6zlemledi:<\/p>\n<ul>\n<li>*5 y\u0131ll\u0131k Genel Sa\u011fkal\u0131m:* Genel oran %19 idi.<\/li>\n<li>*Hastal\u0131\u011f\u0131 tamamen kontrol edilen hastalarda 5 y\u0131ll\u0131k sa\u011fkal\u0131m:* *%38&#8217;e* y\u00fckseldi.<\/li>\n<li>*Sonu\u00e7:* Metastatik lezyonlar\u0131n ba\u015far\u0131l\u0131 lokal kontrol\u00fc, *\u00f6nemli bir iyile\u015ftirici potansiyele* sahipti ve HT&#8217;nin artan lokal etkinli\u011finin \u00f6nemini vurgulad\u0131.<\/li>\n<\/ul>\n<h5>4. Toksisite ve G\u00fcvenlik<\/h5>\n<ul>\n<li>Is\u0131n\u0131n eklenmesi, radyasyona kar\u015f\u0131 *akut veya ge\u00e7 reaksiyonlar\u0131 anlaml\u0131 \u00f6l\u00e7\u00fcde art\u0131rmad\u0131*.<\/li>\n<li>Is\u0131tma tedavisi genellikle *iyi tolere edildi*.<\/li>\n<\/ul>\n<p>*Not:* \u00c7al\u0131\u015fma, termal protokol hedefine (43\u00b0C) ula\u015fmada zorluklardan bahsetti ve bunu tedavilerin sadece %14&#8217;\u00fcnde ba\u015fard\u0131.<\/p>\n<h3>4.6 Tekrarlayan Meme Kanseri<\/h3>\n<h4>4.6.1. Tekrarlayan meme kanserinde termoradyoterapinin etkinli\u011fini do\u011frulayan meta-analiz<\/h4>\n<p>Bir meta-analiz, kombine tedavi (Radyoterapi + Hipertermi) i\u00e7in belirtilen Tam Yan\u0131t Oran\u0131n\u0131 (CR) g\u00f6steren Faz III klinik \u00e7al\u0131\u015fmalar\u0131ndan elde edilen verileri peki\u015ftirmektedir.<\/p>\n<p>*\u00c7al\u0131\u015fma:* <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis.<\/strong><\/a><\/p>\n<ul>\n<li>*Yazarlar:* Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S.<\/li>\n<li>*Sonu\u00e7:* Termoradyoterapi (RT + Hipertermi), tek ba\u015f\u0131na radyoterapiye k\u0131yasla Tam Yan\u0131t Oran\u0131n\u0131 (CR) yakla\u015f\u0131k *%22* art\u0131r\u0131r; iki tedavi kolunu kar\u015f\u0131la\u015ft\u0131ran \u00e7al\u0131\u015fmalarda, RT + Hipertermi (HT) ile *%60.2* CR oran\u0131 elde edilirken, sadece RT (Radyoterapi) ile %38.1 CR oran\u0131 elde edilmi\u015ftir.<\/li>\n<\/ul>\n<h4>4.6.2 Meme Kanserinin Torasik N\u00fcks\u00fc<\/h4>\n<p>Hipertermi, genellikle RT ile kombinasyon halinde, meme kanserinin torasik n\u00fcks\u00fcn\u00fcn tedavisi i\u00e7in *D\u00fczey 1A* kan\u0131tlar\u0131na sahiptir. \u00c7al\u0131\u015fmalar, RT, HT ile birle\u015ftirildi\u011finde *%40 ile %86 aras\u0131nda* de\u011fi\u015fen y\u00fcksek Tam Yan\u0131t Oranlar\u0131 (CR) ve *%70 ile %76 aras\u0131nda* Lokal Kontrol Oranlar\u0131 (LC) g\u00f6stermektedir. Ayr\u0131ca, 5 y\u0131ll\u0131k OS oranlar\u0131 *%50&#8217;ye* kadar ula\u015fabilir.<\/p>\n<h4>4.6.3. Loko-B\u00f6lgesel Tedavideki Genel E\u011filim &#8211; D\u00fczey 1 Kan\u0131tlar\u0131na Sahip Di\u011fer Onkolojik Endikasyonlar<\/h4>\n<ul>\n<li>*Kan\u0131tlar\u0131n Konsolidasyonu:* <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">\u0130kinci bir sistematik inceleme<\/a> (<em>ilki Hildenbrandt ve ark.<\/em>), *6 Faz III \u00e7al\u0131\u015fmas\u0131n\u0131n 5&#8217;inin* Hipertermi standart tedaviye eklendi\u011finde *Genel Sa\u011fkal\u0131mda (OS)* ve\/veya *Tam Yan\u0131tta (CR)* bir art\u0131\u015f g\u00f6sterdi\u011fini ortaya koymaktad\u0131r.<\/li>\n<li>*Palyatif Uygulamalar:* \u00c7al\u0131\u015fmalar, Hiperterminin RT ile birle\u015ftirildi\u011finde, a\u011fr\u0131l\u0131 kemik metastazlar\u0131nda *A\u011fr\u0131ya Tam Yan\u0131tta* \u00f6nemli bir art\u0131\u015fa yol a\u00e7t\u0131\u011f\u0131n\u0131 belirtmektedir.<\/li>\n<\/ul>\n<h3><\/h3>\n<h3>4.7. Mesane Kanseri: Hipertermik \u0130ntravezikal Kemoterapi (HIVEC)<\/h3>\n<p>Hipertermik \u0130ntravezikal Kemoterapi (HIVEC), kas invaziv olmayan mesane kanseri (NMIBC) i\u00e7in mesane instilasyonu s\u0131ras\u0131nda Mitomisin C&#8217;nin (MMC) \u0131s\u0131t\u0131lmas\u0131n\u0131 (tipik olarak 43\u00b0C&#8217;de) i\u00e7erir [6].<\/p>\n<h4>4.7.1. HIVEC-1 Faz III \u00c7al\u0131\u015fmas\u0131 Sonu\u00e7lar\u0131<\/h4>\n<p>HIVEC-1 \u00e7al\u0131\u015fmas\u0131, bir Faz 3 randomize deneme olup, normotermide MMC ile hipertermide MMC&#8217;yi (43\u00b0C, 30 veya 60 dakika boyunca) kar\u015f\u0131la\u015ft\u0131rmay\u0131 ama\u00e7lam\u0131\u015ft\u0131r. Birincil u\u00e7 nokta (RFS): ITT pop\u00fclasyonunda 24 ayl\u0131k RFS, kontrol grubunda (normotermi) %77 iken, HT grubunda %82 (30 dk) ve %80 (60 dk) idi. \u00c7al\u0131\u015fma, HT&#8217;nin 24 ayl\u0131k RFS a\u00e7\u0131s\u0131ndan normotermide MMC&#8217;den istatistiksel olarak \u00fcst\u00fcn olmad\u0131\u011f\u0131n\u0131 g\u00f6sterdi (p de\u011feri 0.6) [6].<\/p>\n<h4>4.7.2. N\u00fcanslar ve \u0130lerlemesiz Sa\u011fkal\u0131m<\/h4>\n<p>NMIBC-RI i\u00e7in RFS sonucunun aksine, di\u011fer \u00e7al\u0131\u015fmalardan elde edilen veriler, \u00f6zellikle BCG tedavisine ba\u015far\u0131s\u0131z olan y\u00fcksek riskli hastalar i\u00e7in faydalar\u0131 vurgulamaktad\u0131r. Bir analiz, ITT analizinde *HIVEC i\u00e7in BCG&#8217;ye k\u0131yasla anlaml\u0131 \u00f6l\u00e7\u00fcde daha iyi bir ilerlemesiz sa\u011fkal\u0131m (PFS) g\u00f6sterdi (%95.7&#8217;ye kar\u015f\u0131 %71.8; p = 0.043) [7]*.<\/p>\n<p>&nbsp;<\/p>\n<p>*Tablo 2, hipertermi entegrasyonu i\u00e7in ba\u015fl\u0131ca Faz III klinik sonu\u00e7lar\u0131n\u0131 \u00f6zetlemektedir.*<\/p>\n<p>Tablo 2: Onkolojide Hipertermi i\u00e7in Ba\u015fl\u0131ca Faz III Klinik Sonu\u00e7lar\u0131 (HT + Standart Tedavi vs. Sadece Standart Tedavi)<\/p>\n<p>&nbsp;<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Kanser Tipi (HT Y\u00f6ntemi)<\/strong><\/td>\n<td width=\"104\"><strong>\u00c7al\u0131\u015fma Tipi\/G\u00f6sterge<\/strong><\/td>\n<td width=\"104\"><strong>HT + Standart Tedavi<\/strong><\/td>\n<td width=\"104\"><strong>Sadece Standart Tedavi<\/strong><\/td>\n<td width=\"104\"><strong>\u0130statistiksel Anlaml\u0131l\u0131k\/G\u00f6sterge Sonucu<\/strong><\/td>\n<td width=\"104\"><strong>Referans<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Yumu\u015fak Doku Sarkomu (L-R HT + KT) 11.3 y\u0131l<\/td>\n<td width=\"104\">Randomize Faz III (<\/p>\n<p>5 y\u0131ll\u0131k OS<\/p>\n<p>&nbsp;<\/p>\n<p>10 y\u0131ll\u0131k OS)<\/td>\n<td width=\"104\">%62.7<\/p>\n<p>&nbsp;<\/p>\n<p>%52.6<\/td>\n<td width=\"104\">%51.3<\/p>\n<p>&nbsp;<\/p>\n<p>%42.7<\/td>\n<td width=\"104\">Sadece neoadjuvan kemoterapiye k\u0131yasla, b\u00f6lgesel hipertermi eklenmesi lokal olarak *hastal\u0131ks\u0131z sa\u011fkal\u0131m\u0131 DFS* iyile\u015ftirdi (Risk Oran\u0131 [HR], 0.65; %95 CI, 0.49\u20130.86; P = 0.002).<\/p>\n<p>Kemoterapi art\u0131 hipertermi i\u00e7in randomize edilen hastalar, sadece neoadjuvan kemoterapi i\u00e7in randomize edilenlere g\u00f6re daha uzun *Genel Sa\u011fkal\u0131m OS* elde etti (HR, 0.73; %95 CI, 0.54\u20130.98; P = 0.04), 5 y\u0131ll\u0131k sa\u011fkal\u0131m s\u0131ras\u0131yla %62.7&#8217;ye kar\u015f\u0131 %51.3 ve 10 y\u0131ll\u0131k sa\u011fkal\u0131m %52.6&#8217;ya kar\u015f\u0131 %42.7 oldu.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Serviks Kanseri (LACC) (L-R HT + RT) 12 y\u0131l<\/td>\n<td width=\"104\">Randomize Faz III (<strong>12 y\u0131ll\u0131k OS<\/strong>)<\/td>\n<td width=\"104\">%37<\/td>\n<td width=\"104\">%20<\/td>\n<td width=\"104\">Anlaml\u0131 \u00f6l\u00e7\u00fcde daha iyi OS (P &lt; 0.05)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Rektum Kanseri (CRT + HT) 5 y\u0131l<\/td>\n<td width=\"104\">Randomize Faz III<\/p>\n<p>(<strong>5 y\u0131ll\u0131k OS<\/strong>,<\/p>\n<p>&nbsp;<\/p>\n<p>5 y\u0131ll\u0131k DFS<\/p>\n<p>&nbsp;<\/p>\n<p>5 y\u0131ll\u0131k Lokal N\u00fckss\u00fcz Sa\u011fkal\u0131m LRF<\/p>\n<p>&nbsp;<\/p>\n<p>5 y\u0131ll\u0131k Kolostomisiz Sa\u011fkal\u0131m CFSR<\/p>\n<p>&nbsp;<\/td>\n<td width=\"104\">%95.8<\/p>\n<p>&nbsp;<\/p>\n<p>%89.1<\/p>\n<p>&nbsp;<\/p>\n<p>%97.7<\/p>\n<p>&nbsp;<\/p>\n<p>%87.7<\/td>\n<td width=\"104\">%74.5<\/p>\n<p>&nbsp;<\/p>\n<p>%70.4<\/p>\n<p>&nbsp;<\/p>\n<p>%78.7<\/p>\n<p>&nbsp;<\/p>\n<p>%69.0<\/td>\n<td width=\"104\">OS&#8217;de iyile\u015fme (P = 0.045)<\/p>\n<p>&nbsp;<\/p>\n<p>DFS&#8217;de iyile\u015fme ( <i>P<\/i>\u202f=\u20090.027),<\/p>\n<p>&nbsp;<\/p>\n<p>LRF&#8217;de iyile\u015fme ( <i>P<\/i>\u202f=\u20090.006),<\/p>\n<p>&nbsp;<\/p>\n<p>CFSR&#8217;de iyile\u015fme ( <i>P<\/i>\u202f=\u20090.016))<\/p>\n<p>&nbsp;<\/td>\n<td width=\"104\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Ba\u015f-Boyun T\u00fcm\u00f6r\u00fc NPC (CRT + HT)<\/td>\n<td width=\"104\">Randomize Faz III (5 y\u0131ll\u0131k DFS<\/p>\n<p>ve<\/p>\n<p>5 y\u0131ll\u0131k OS<\/p>\n<p>ve<\/p>\n<p>CR )<\/td>\n<td width=\"104\">%51.3<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>%68.4<\/p>\n<p>&nbsp;<\/p>\n<p>%81.6<\/td>\n<td width=\"104\">%25.5<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>%50<\/p>\n<p>&nbsp;<\/p>\n<p>%62.8<\/td>\n<td width=\"104\">Bu Faz III \u00e7al\u0131\u015fmas\u0131 anlaml\u0131 bir iyile\u015fme g\u00f6sterdi.<\/td>\n<td width=\"104\"><strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\">Kang 2013<\/a><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Ba\u015f-Boyun T\u00fcm\u00f6r\u00fc <strong>Oral Kavite\/Orofarinks\/Hipofarinks<\/strong> (RT + HT)<\/td>\n<td width=\"104\">Randomize Faz III (CR)<\/td>\n<td width=\"104\">%78.6<\/td>\n<td width=\"104\">%42.4<\/td>\n<td width=\"104\">Fark istatistiksel olarak anlaml\u0131yd\u0131 (&lt; 0.05). Kaplan-Meier sa\u011fkal\u0131m analizi de radyoterapi-HT lehine anlaml\u0131 bir iyile\u015fme g\u00f6sterdi.<\/td>\n<td width=\"104\"><strong><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\">Huilgol 2010<\/a><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Malign Melanom (RT + HT)<\/td>\n<td width=\"104\">Randomize Faz III (CR)<\/td>\n<td width=\"104\">%46<\/td>\n<td width=\"104\">%28<\/td>\n<td width=\"104\">2 y\u0131lda lokal kontrolde anlaml\u0131 iyile\u015fme (p = 0.008)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nihs.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nihs.gov\/7776772\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Tekrarlayan Meme Kanseri (RT + HT) &#8211; HT, NCCN k\u0131lavuzlar\u0131na dahil<\/td>\n<td width=\"104\">Randomize Faz III (CR)<\/td>\n<td width=\"104\">%60.2<\/td>\n<td width=\"104\">%38.1<\/td>\n<td width=\"104\">CR oran\u0131 %57 artt\u0131<\/td>\n<td width=\"104\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Mesane Kanseri AR NMI (HIVEC-1)<\/td>\n<td width=\"104\">Randomize Faz III (24 ayl\u0131k RFS)<\/td>\n<td width=\"104\">%80-%82<\/td>\n<td width=\"104\">%77<\/td>\n<td width=\"104\">Anlaml\u0131 fark yok (p = 0.6)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Kemik Metastazlar\u0131 (TBH + RT)<\/td>\n<td width=\"104\">Randomize Faz III (A\u011fr\u0131 i\u00e7in CR)<\/td>\n<td width=\"104\">%47.4<\/td>\n<td width=\"104\">%5.3<\/td>\n<td width=\"104\">CR&#8217;de iyile\u015fme (P &lt; 0.05); Yan\u0131t s\u00fcresi 10 g\u00fcne k\u0131sald\u0131<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Kemik Metastazlar\u0131 (RF HT + RT)<\/td>\n<td width=\"104\">Randomize Faz III (A\u011fr\u0131 i\u00e7in CR)<\/td>\n<td width=\"104\">%37.9<\/p>\n<p>&nbsp;<\/p>\n<p>%58.6<\/td>\n<td width=\"104\">%7.1<\/p>\n<p>&nbsp;<\/p>\n<p>%32.1<\/td>\n<td width=\"104\">3 ayda CR&#8217;de iyile\u015fme (P = 0.006);<\/p>\n<p>Tedaviden sonraki 3 ayda k\u00fcm\u00fclatif CR (P=0.045);<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29066122\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nihs.gov\/29066122\/<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div id=\"IDtable-wrap-foot\" class=\"NLM_table-wrap-foot\">\n<div id=\"TF4\">\n<p class=\"first last\"><span dir=\"auto\">mEHT: Mod\u00fcle Edilmi\u015f Elektro-Hipertermi; KT: Kemoterapi; RT: Radyoterapi; HT: Hipertermi; RITE: Radyofrekans Kaynakl\u0131 Termal Kemoterapi; HIPEC: Hipertermik \u0130ntraperitoneal Kemoterapi; OS: Genel Sa\u011fkal\u0131m; DFS: Hastal\u0131ks\u0131z Sa\u011fkal\u0131m; CR: Tam Yan\u0131t; LC: Lokal Kontrol; PFS: \u0130lerlemesiz Sa\u011fkal\u0131m; ST: Sa\u011fkal\u0131m S\u00fcresi<\/span><\/p>\n<\/div>\n<\/div>\n<h2><strong>5. Agresif ve Tekrarlayan Ko\u015fullardaki Kan\u0131tlar (Geli\u015fmekte Olan Endikasyonlar)<\/strong><\/h2>\n<p>Bu b\u00f6l\u00fcm, D\u00fczey 1A kan\u0131tlar\u0131n\u0131n s\u0131n\u0131rl\u0131 oldu\u011fu veya geli\u015fmekte oldu\u011fu, ancak y\u00fcksek kaliteli kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7al\u0131\u015fmalar\u0131n HT i\u00e7in \u00f6nemli bir rol\u00fc i\u015faret etti\u011fi zorlu t\u00fcm\u00f6r lokalizasyonlar\u0131n\u0131 analiz etmektedir.<\/p>\n<h3>5.1. Gliomlar (Glioblastoma Multiforme &#8211; GBM ve Astrositom &#8211; AST)<\/h3>\n<p>Gliomlar, \u00f6zellikle Glioblastoma Multiforme (GBM), tedaviye kar\u015f\u0131 a\u015f\u0131r\u0131 diren\u00e7leriyle bilinir. GBM i\u00e7in brakiterapi +- Hipertermi&#8217;yi de\u011ferlendiren 1998 tarihli bir randomize \u00e7al\u0131\u015fma, kombine kol lehine bir sa\u011fkal\u0131m faydas\u0131 belgeledi [9].<\/p>\n<h4>5.1.1. Mod\u00fcle Edilmi\u015f RF Hipertermi (mHT) Verileri<\/h4>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">Yak\u0131n tarihli meta-analizler<\/a>, mEHT ve T\u00fcm\u00f6r Tedavi Alanlar\u0131n\u0131n (TTF), Glioblastoma Multiforme&#8217;de sa\u011fkal\u0131m\u0131 iyile\u015ftirebilece\u011fini \u00f6ne s\u00fcrmektedir [10]. Faydan\u0131n en \u00e7ok yeni te\u015fhis edilen hastalarda oldu\u011fu g\u00f6r\u00fclmektedir. \u00d6rne\u011fin, yeni te\u015fhis edilen hastalar i\u00e7in mHT \u00e7al\u0131\u015fmalar\u0131nda *1 y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131 %73* iken, kontrol kolunda %37 idi (p = 0.0021) [10].<br \/>\nTekrarlayan durumlarda, *kar\u015f\u0131la\u015ft\u0131rmal\u0131 bir g\u00f6zlemsel analiz, mHT&#8217;nin daha uzun bir OS sundu\u011funu g\u00f6sterdi (medyan GBM 14 ay kar\u015f\u0131l\u0131k 12 ay, p=0.026). Astrositomlar (AST) i\u00e7in mHT, palyatif en iyi destekleyici bak\u0131m grubunda 17\/34 aya kar\u015f\u0131l\u0131k 72\/91.6 ay ortalama\/medyan OS ile \u00f6nemli bir avantaj g\u00f6sterdi (p=0.0006). Tekrarlayan GBM&#8217;de bile, mHT ile tedavi edilen hastalar\u0131n 5 y\u0131ll\u0131k OS&#8217;si en iyi destekleyici bak\u0131m grubundaki %1.2&#8217;ye kar\u015f\u0131l\u0131k %3.5 idi [11].*<\/p>\n<p>*Gliomlar\u0131n zorlu klinik ortam\u0131nda bile, kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7al\u0131\u015fmalardan elde edilen g\u00fc\u00e7l\u00fc sa\u011fkal\u0131m sinyalleri, HT&#8217;nin klinik k\u0131lavuzlara D\u00fczey 1A endikasyonu olarak dahil edilmesini hakl\u0131 \u00e7\u0131karmaktad\u0131r.*<\/p>\n<h3>5.2. Pankreas Kanseri (PK)<\/h3>\n<p>Pankreas kanseri, HT&#8217;nin \u015fu anda &#8220;genel palyatif klinik kan\u0131t (Faz II \u00e7al\u0131\u015fmalar\u0131ndan)&#8221; olarak s\u0131n\u0131fland\u0131r\u0131ld\u0131\u011f\u0131, son derece \u00f6l\u00fcmc\u00fcl sistemik bir hastal\u0131kt\u0131r. Ancak, son y\u0131llarda yap\u0131lan b\u00fcy\u00fck kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7al\u0131\u015fmalar g\u00fc\u00e7l\u00fc bir klinik sinyal \u00fcretmi\u015ftir.<\/p>\n<h4>5.2.1. Metastatik PK&#8217;de mEHT&#8217;nin Kar\u015f\u0131la\u015ft\u0131rmal\u0131 Analizi<\/h4>\n<p>B\u00fcy\u00fck bir retrospektif \u00e7ok merkezli g\u00f6zlemsel \u00e7al\u0131\u015fma (N=217 evre III-IV PK hastas\u0131), mEHT + CHT&#8217;yi (\u00e7o\u011funlukla gemsitabin bazl\u0131) sadece CHT ile kar\u015f\u0131la\u015ft\u0131rd\u0131.<br \/>\n*\u25cf Genel Sa\u011fkal\u0131m (OS): OS, mEHT grubunda anlaml\u0131 \u00f6l\u00e7\u00fcde iyile\u015fmi\u015ftir (CHT grubunda 9 aya kar\u015f\u0131l\u0131k 20 ay, P &lt; 0.001).*<br \/>\n*\u25cf \u0130lerlemesiz Sa\u011fkal\u0131m (PFS): PFS de anlaml\u0131 \u00f6l\u00e7\u00fcde iyile\u015fmi\u015ftir (5 aya kar\u015f\u0131l\u0131k 7 ay, P &lt; 0.05).*<br \/>\n*\u25cf T\u00fcm\u00f6r Yan\u0131t\u0131: mEHT ile tedavi edilen hastalar, anlaml\u0131 \u00f6l\u00e7\u00fcde daha y\u00fcksek bir k\u0131smi yan\u0131t (PR) (%24&#8217;e kar\u015f\u0131l\u0131k %45, P = 0.0018) ve anlaml\u0131 \u00f6l\u00e7\u00fcde daha d\u00fc\u015f\u00fck bir ilerleyici hastal\u0131k (PD) (%31&#8217;e kar\u015f\u0131l\u0131k %4, P &lt; 0.01) kaydetti.*<\/p>\n<h4>5.2.2. HT&#8217;nin Ya\u015f \u00dczerindeki Etkisi<\/h4>\n<p>Ya\u015fa g\u00f6re sa\u011fkal\u0131m analizi benzersiz bir klinik y\u00f6n\u00fc ortaya \u00e7\u0131kard\u0131: RF mod\u00fcle edilmi\u015f hiperterminin (mHT) sa\u011flad\u0131\u011f\u0131 OS faydas\u0131, hastalar\u0131n &lt;= 70 ya\u015f veya &gt; 70 ya\u015f olmas\u0131na bak\u0131lmaks\u0131z\u0131n devam etti (her iki grupta da medyan OS 20 ayd\u0131). Buna kar\u015f\u0131l\u0131k, sadece CHT alan ya\u015fl\u0131 hastalar\u0131n OS&#8217;si, gen\u00e7 benzerlerine g\u00f6re anlaml\u0131 \u00f6l\u00e7\u00fcde daha d\u00fc\u015f\u00fckt\u00fc (12 aya kar\u015f\u0131l\u0131k 8 ay), bu da CHT&#8217;nin etkinli\u011finin ya\u015fla birlikte azald\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. *MHT&#8217;nin, muhtemelen uygun toksisite profili nedeniyle, standart CHT&#8217;de g\u00f6zlemlenen ya\u015fa ba\u011fl\u0131 d\u00fc\u015f\u00fc\u015f olmadan g\u00fc\u00e7l\u00fc bir etkinlik sa\u011flad\u0131\u011f\u0131 d\u00fc\u015f\u00fcnd\u00fcr\u00fcc\u00fcd\u00fcr.*<br \/>\n*Klinik a\u00e7\u0131dan b\u00fcy\u00fck iyile\u015fme (medyan OS&#8217;nin 9 aydan 20 aya iki kat\u0131na \u00e7\u0131kmas\u0131), uluslararas\u0131 randomize Faz III \u00e7al\u0131\u015fmalar\u0131n\u0131n acilen d\u00fczenlenmesi i\u00e7in g\u00fc\u00e7l\u00fc bir talep yaratt\u0131 (\u00f6rne\u011fin, NCT02862015, Metastatik Pankreas Kanserinde Onkotermi \u00dczerine \u00c7ok Merkezli Randomize Klinik \u00c7al\u0131\u015fma).*<\/p>\n<p>&nbsp;<\/p>\n<h2>6. G\u00fcvenlik Profili ve Kaliteye Ayarlanm\u0131\u015f Ya\u015fam Y\u0131llar\u0131 (QALY): HT&#8217;nin Y\u00fcksek Terap\u00f6tik \u0130ndeksi<\/h2>\n<h2>HT&#8217;nin Y\u00fcksek Terap\u00f6tik \u0130ndeksi<\/h2>\n<p>Yayg\u0131n klinik kabul, uygun bir terap\u00f6tik indeksin korunmas\u0131na ba\u011fl\u0131d\u0131r. *Faz III kan\u0131tlar\u0131, HT&#8217;nin bu gereksinimi kar\u015f\u0131lad\u0131\u011f\u0131n\u0131 ve ciddi toksisiteyi \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rmad\u0131\u011f\u0131n\u0131 \u00e7o\u011funlukla do\u011frulamaktad\u0131r.*<\/p>\n<h3>6.1. Sistemik Toksisite Analizi (Grade 3\u20134)<\/h3>\n<p>Randomize \u00e7al\u0131\u015fmalar\u0131n sistematik analizi, HT&#8217;nin RT veya CHT&#8217;nin neden oldu\u011fu *sistemik toksisiteyi \u015fiddetlendirmedi\u011fini* do\u011frulamaktad\u0131r:<\/p>\n<ul>\n<li>*Serviks Kanseri (LACC):* Akut veya ge\u00e7 grade 3\u20134 toksisitede anlaml\u0131 bir fark g\u00f6zlenmedi (RR \u2248 1.0).<\/li>\n<li>*Rektum Kanseri:* Toksisite profili kar\u015f\u0131la\u015ft\u0131r\u0131labilirdi. \u015eiddetli grade 3\u20134 cilt veya gastrointestinal reaksiyonlarda art\u0131\u015f bulunmad\u0131.<\/li>\n<li>*Pankreas Kanseri (mHT):* Kemoterapiye atfedilen hematolojik, hepatik, pulmoner veya metabolik toksisiteyi art\u0131rmad\u0131.<\/li>\n<\/ul>\n<h3>6.2. Hipertermi Y\u00f6ntemine \u00d6zg\u00fc Yan Etkiler<\/h3>\n<p>Do\u011frudan hipertermi ile ilgili yan etkiler \u00e7o\u011funlukla lokalizedir ve genellikle y\u00f6netilebilirdir:<br \/>\n*\u25cf Loko-b\u00f6lgesel Hipertermi (L-R HT):* Tekrarlayan meme kanseri vakalar\u0131n\u0131n %10 ila %32&#8217;sinde grade 3\u20134 yan etkiler bildirilmi\u015ftir, \u00e7o\u011funlukla lokal cilt reaksiyonlar\u0131 (hafif yan\u0131klar veya rahats\u0131zl\u0131k) ile ilgilidir.<br \/>\n\u25cf *Mod\u00fcle Edilmi\u015f RF Hipertermi (mHT)*: mHT, \u00f6zellikle uygun bir g\u00fcvenlik profiline sahiptir. Pankreas kanseri \u00e7al\u0131\u015fmas\u0131nda, mHT seanslar\u0131n\u0131n sadece %2.6&#8217;s\u0131nda yan etkiler bildirilmi\u015ftir.<br \/>\n\u25cf *HIVEC-1 \u00c7al\u0131\u015fmas\u0131 (Mesane Kanseri):* Ciddi yan etkiler gruplar aras\u0131nda kar\u015f\u0131la\u015ft\u0131r\u0131labilir olmas\u0131na ra\u011fmen (p = 0.5), toplam yan etkiler (\u00e7o\u011funlukla lokal rahats\u0131zl\u0131k ve kramplar) HT kolunda (kontrol %33&#8217;e kar\u015f\u0131l\u0131k %35%\u201348%, p = 0.05) biraz daha y\u00fcksekti, bu da lokalize ancak ciddi morbidite a\u00e7\u0131s\u0131ndan anlaml\u0131 olmayan etkileri do\u011frulamaktad\u0131r.<\/p>\n<h3>6.3. Kaliteye Ayarlanm\u0131\u015f Ya\u015fam Y\u0131llar\u0131 (QALY) \u00dczerindeki Etki<\/h3>\n<p>Ya\u015fam s\u00fcresindeki art\u0131\u015f\u0131 ya\u015fam kalitesiyle birle\u015ftiren QALY (Quality-Adjusted Life Years) kavram\u0131, terap\u00f6tik fayda hakk\u0131nda ekonomik ve insani bir bak\u0131\u015f a\u00e7\u0131s\u0131 sunar. HT&#8217;nin belgelenmi\u015f klinik faydalar\u0131 \u2013 iyile\u015ftirilmi\u015f sa\u011fkal\u0131m, daha y\u00fcksek CR oranlar\u0131 ve m\u00fckemmel lokal kontrol \u2013 hastalar i\u00e7in uzun vadeli maliyet tasarrufu ve QALY&#8217;de iyile\u015fme olas\u0131l\u0131\u011f\u0131n\u0131n y\u00fcksek oldu\u011funu g\u00f6sterir, bu da klinik kabul lehine arg\u00fcman\u0131 g\u00fc\u00e7lendirir.<br \/>\nTablo 3, HT entegrasyonunun g\u00fcvenlik profilini standart tedavi ile kar\u015f\u0131la\u015ft\u0131rmaktad\u0131r.<\/p>\n<p>Tablo 3: G\u00fcvenlik ve Toksisite Kar\u015f\u0131la\u015ft\u0131rmas\u0131 (HT Entegrasyonu vs. Standart Tedavi)<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Kanser Tipi<\/strong><\/td>\n<td width=\"104\"><strong>Standart Tedavi (Kontrol)<\/strong><\/td>\n<td width=\"104\"><strong>M\u00fcdahale (HT + Standart Tedavi)<\/strong><\/td>\n<td width=\"104\"><strong>Grade 3-4 Toksisite Sonu\u00e7lar\u0131<\/strong><\/td>\n<td width=\"104\"><strong>Klinik Sonu\u00e7<\/strong><\/td>\n<td width=\"104\"><strong>Referans<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Lokal Olarak \u0130lerlemi\u015f Serviks Kanseri<\/td>\n<td width=\"104\">Sadece CCRT<\/td>\n<td width=\"104\">CCRT + L-R HT<\/td>\n<td width=\"104\">Akut veya ge\u00e7 toksisitede anlaml\u0131 fark yok (RR \\sim 1.0)<\/td>\n<td width=\"104\">Uygun terap\u00f6tik indeks; Sistemik toksisite \u015fiddetlenmez.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Rektum\/An\u00fcs Kanseri<\/td>\n<td width=\"104\">CRT<\/td>\n<td width=\"104\">CRT + L-R HT<\/td>\n<td width=\"104\">Kar\u015f\u0131la\u015ft\u0131r\u0131labilir toksisite profili; Ciddi GI veya cilt reaksiyonlar\u0131nda art\u0131\u015f yok<\/td>\n<td width=\"104\">HT, pelvik CRT protokolleri ile kombinasyon halinde g\u00fcvenlidir.<\/td>\n<td width=\"104\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Sarkom (EORTC)<\/td>\n<td width=\"104\">CHT<\/td>\n<td width=\"104\">RHT + CHT<\/td>\n<td width=\"104\">Ciddi toksisite oran\u0131, \u00e7al\u0131\u015fman\u0131n tamamlanmas\u0131n\u0131 engellemedi<\/td>\n<td width=\"104\">Y\u00fcksek tolerans; Uzun vadeli g\u00fcvenlik do\u011fruland\u0131.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Mesane Kanseri AR NMI (HIVEC-1)<\/td>\n<td width=\"104\">Normotermik MMC<\/td>\n<td width=\"104\">Hipertermik MMC<\/td>\n<td width=\"104\">Ciddi yan etkilerde fark yok (p = 0.5)<\/td>\n<td width=\"104\">Ciddi morbidite de\u011fi\u015fmeden kald\u0131.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h2>7. Sonu\u00e7lar, Klinik Entegrasyon ve Gelecek Y\u00f6nelimleri<\/h2>\n<h3>7.1. Nihai D\u00fczey 1A Endikasyonlar\u0131n\u0131n \u00d6zeti<\/h3>\n<p>Faz III randomize \u00e7al\u0131\u015fmalar ve meta-analizlere dayanan literat\u00fcr\u00fcn titiz analizi, hiperterminin deneysel bir tedavi de\u011fil, belirli t\u00fcm\u00f6r lokalizasyonlar\u0131 i\u00e7in multimodal onkolojinin \u00f6nemli bir unsuru oldu\u011funu do\u011frulamaktad\u0131r.<br \/>\n*HT, yumu\u015fak doku sarkomu, lokal olarak ilerlemi\u015f serviks kanseri, ba\u015f-boyun t\u00fcm\u00f6rleri, rektum\/an\u00fcs kanseri, melanom (loko-b\u00f6lgesel hastal\u0131k) ve tekrarlayan meme kanserinin tedavisinde sa\u011fkal\u0131m, hastal\u0131ks\u0131z sa\u011fkal\u0131m ve tam yan\u0131t a\u00e7\u0131s\u0131ndan kesin fayda i\u00e7in D\u00fczey 1A kan\u0131tlar\u0131na sahiptir [2].* Bu endikasyonlar i\u00e7in HT, standart multimodal tedavinin \u00f6nemli bir bile\u015feni olarak kabul edilmelidir.<\/p>\n<h3>7.2. Etkinlik N\u00fcanslar\u0131 ve Teknik \u00d6nem<\/h3>\n<p>HT tedavisinin etkinli\u011fi, b\u00fcy\u00fck \u00f6l\u00e7\u00fcde teknik hassasiyete ve \u0131s\u0131tma y\u00f6ntemine ba\u011fl\u0131d\u0131r. Derin solid t\u00fcm\u00f6rlerdeki (\u00f6rne\u011fin, LACC, HNC) HT&#8217;nin dikkate de\u011fer ve tutarl\u0131 ba\u015far\u0131s\u0131, NMIBC-AR&#8217;deki HIVEC ile elde edilen kar\u0131\u015f\u0131k sonu\u00e7larla tezat olu\u015fturmaktad\u0131r.<br \/>\nBu tezat, optimal klinik faydan\u0131n sadece \u0131s\u0131 uygulamas\u0131yla elde edilmedi\u011fini, t\u00fcm\u00f6r hacmi boyunca tek tip ve biyolojik olarak etkili bir termal doz sa\u011flamak i\u00e7in titiz bir kalite kontrol\u00fc (QC) ve teknik optimizasyon gerektirdi\u011fini vurgulamaktad\u0131r. Veriler ayr\u0131ca, HT faydas\u0131n\u0131n riske g\u00f6re katmanland\u0131r\u0131labilece\u011fini ve tekrarlayan durumlar, y\u00fcksek riskli sarkomlar veya BCG&#8217;ye diren\u00e7li NMIBC gibi y\u00fcksek diren\u00e7li ortamlarda en belirgin oldu\u011funu g\u00f6stermektedir.<\/p>\n<h3>7.3. Umut Veren Endikasyonlar ve Gelecekteki Klinik \u00c7al\u0131\u015fmalar<\/h3>\n<h4>7.3.1. Pankreas Kanseri<\/h4>\n<p>Metastatik pankreas kanserinde RF mod\u00fcle edilmi\u015f hipertermi (mHT) + CHT i\u00e7in *medyan OS&#8217;de iki kat\u0131na \u00e7\u0131kmay\u0131 (9 aydan 20 aya)* i\u015faret eden kar\u015f\u0131la\u015ft\u0131rmal\u0131 g\u00f6zlemsel veriler, *ola\u011fan\u00fcst\u00fc g\u00fc\u00e7l\u00fc bir klinik sinyal* olu\u015fturmaktad\u0131r. Bu sonu\u00e7lar, bu genel sa\u011fkal\u0131m faydalar\u0131n\u0131 en y\u00fcksek kan\u0131t d\u00fczeyinde do\u011frulamak i\u00e7in uluslararas\u0131 randomize Faz III \u00e7al\u0131\u015fmalar\u0131n\u0131n (NCT02862015 gibi) acilen ba\u015flat\u0131lmas\u0131n\u0131 hakl\u0131 \u00e7\u0131karmaktad\u0131r.<\/p>\n<h4>7.3.2. \u0130mm\u00fcno-Onkoloji ile Entegrasyon<\/h4>\n<p>HT&#8217;nin, HSP sal\u0131n\u0131m\u0131 ve T lenfositlerinin haz\u0131rlanmas\u0131 yoluyla imm\u00fcnolojik olarak &#8220;so\u011fuk&#8221; t\u00fcm\u00f6rleri &#8220;s\u0131cak&#8221; (iltihapl\u0131) t\u00fcm\u00f6rlere d\u00f6n\u00fc\u015ft\u00fcrme yetene\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, gelecekteki Faz III \u00e7al\u0131\u015fmalar\u0131, kontrol noktas\u0131 inhibit\u00f6rleri gibi modern imm\u00fcnoterap\u00f6tik ajanlarla HT&#8217;nin sinerjisini ara\u015ft\u0131rmal\u0131d\u0131r. Bu kombinasyon, \u00f6zellikle daha \u00f6nce diren\u00e7li olan t\u00fcm\u00f6rlerde imm\u00fcnoterapi yan\u0131t\u0131n\u0131 art\u0131rabilir.<\/p>\n<p>*Klinik Deneyim (E-E-A-T):*<\/p>\n<p>*Andromedichyperthermia&#8217;da, bu D\u00fczey 1A protokollerini (<a href=\"https:\/\/andromedichyperthermia.com\/tr\/klinik-calisma-hipertermi-karsinom\/\">LACC i\u00e7in Hipertermi + CCRT + BRT kombinasyonu gibi<\/a>) bak\u0131m standard\u0131 olarak inceliyor ve klinik \u00e7al\u0131\u015fmalardan kan\u0131tlanm\u0131\u015f faydalar\u0131 do\u011frudan hastalar\u0131m\u0131z\u0131n bireyselle\u015ftirilmi\u015f tedavi planlar\u0131na \u00e7eviriyoruz.*<\/p>\n<h3>7.4. Klinik Kabul Standartlar\u0131<\/h3>\n<p>HT&#8217;nin ba\u015far\u0131l\u0131 kurumsal uygulamas\u0131, multidisipliner uzmanl\u0131k (t\u0131bbi fizik\u00e7iler, radyasyon onkologlar\u0131, kemoterapistler) ve t\u00fcm\u00f6r hacmi boyunca termal dozimetri protokollerine s\u0131k\u0131 s\u0131k\u0131ya uyulmas\u0131n\u0131 gerektirir. D\u00fczey 1A sonu\u00e7lar\u0131n\u0131 yeniden \u00fcretmek i\u00e7in, tedavi merkezlerinin uzman kurulu\u015flar taraf\u0131ndan belirlenen y\u00f6nergelere ve uluslararas\u0131 standartlara uymas\u0131 gerekir.<\/p>\n<p>Tablo 4: Geli\u015fmekte Olan Endikasyonlar ve Faz II\/G\u00f6zlemsel Veriler (Sa\u011fkal\u0131m Kriterleri)<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Kanser Tipi (HT Y\u00f6ntemi)<\/strong><\/td>\n<td width=\"104\"><strong>\u00c7al\u0131\u015fma Tipi\/G\u00f6sterge<\/strong><\/td>\n<td width=\"104\"><strong>HT + Standart Tedavi (OS\/PFS\/QoL)<\/strong><\/td>\n<td width=\"104\"><strong>Sadece Standart Tedavi (OS\/PFS\/QoL)<\/strong><\/td>\n<td width=\"104\"><strong>Anahtar Sonu\u00e7\/P De\u011feri<\/strong><\/td>\n<td width=\"104\"><strong>Referans<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Pankreas Kanseri (mEHT + CHT)<\/td>\n<td width=\"104\">Retrospektif Kar\u015f\u0131la\u015ft\u0131rma (OS)<\/td>\n<td width=\"104\">Medyan OS: 20 ay<\/td>\n<td width=\"104\">Medyan OS: 9 ay<\/td>\n<td width=\"104\">OS anlaml\u0131 \u00f6l\u00e7\u00fcde iyile\u015fmi\u015f (g\u00f6receli %77 art\u0131\u015f)<\/td>\n<td width=\"104\">[Fiorentini ve ark., 2021]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Yeni Te\u015fhis Edilmi\u015f Glioblastoma Multiforme (mEHT)<\/td>\n<td width=\"104\">Meta-analiz (1 y\u0131ll\u0131k OS)<\/td>\n<td width=\"104\">%73<\/td>\n<td width=\"104\">%37<\/td>\n<td width=\"104\">Anlaml\u0131 OS faydas\u0131 (p=0.0021)<\/td>\n<td width=\"104\">(<a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Astrositom (mEHT)<\/td>\n<td width=\"104\">Retrospektif Kar\u015f\u0131la\u015ft\u0131rma (OS)<\/td>\n<td width=\"104\">Medyan OS: 72 ay<\/td>\n<td width=\"104\">Medyan OS: 17 ay<\/td>\n<td width=\"104\">OS anlaml\u0131 \u00f6l\u00e7\u00fcde iyile\u015fmi\u015f (p=0.0006)<\/td>\n<td width=\"104\">[Fiorentini ve ark., 2019]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Rektum Kanseri (pCR, Fonksiyonel)<\/td>\n<td width=\"104\">Faz III (Kolostomisiz Sa\u011fkal\u0131m)<\/td>\n<td width=\"104\">%87.7<\/td>\n<td width=\"104\">%69.0<\/td>\n<td width=\"104\">QoL\/Fonksiyonda iyile\u015fme (P=0.016)<\/td>\n<td width=\"104\">[Faz III, Ott 2019]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Serviks Kanseri (LACC)<\/td>\n<td width=\"104\">RCT (DFS\/QoL)<\/td>\n<td width=\"104\">Duygusal\/Fiziksel QoL&#8217;de iyile\u015fme<\/td>\n<td width=\"104\">Stabil\/D\u00fc\u015fen QoL<\/td>\n<td width=\"104\">Toksisite artmadan QoL anlaml\u0131 \u00f6l\u00e7\u00fcde iyile\u015fmi\u015f<\/td>\n<td width=\"104\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8833695\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8833695\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Peritoneal Metastazlar (HIPEC)<\/td>\n<td width=\"104\">G\u00f6zlemsel \u00c7al\u0131\u015fma (Duygusal QoL)<\/td>\n<td width=\"104\">H\u0131zl\u0131 iyile\u015fme (ameliyattan sonra 3 ay)<\/td>\n<td width=\"104\">Yava\u015f iyile\u015fme<\/td>\n<td width=\"104\">H\u0131zl\u0131 psikolojik fayda<\/td>\n<td width=\"104\"><a href=\"https:\/\/dmr.amegroups.org\/article\/view\/6846\/html\" target=\"_blank\" rel=\"noopener\">https:\/\/dmr.amegroups.org\/article\/view\/6846\/html<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h2>8. Onkolojik Hipertermi Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular (SSS)<\/h2>\n<h3>S: Hipertermi, onkolojide deneysel bir tedavi midir?<\/h3>\n<p>*C:* Hay\u0131r. Hipertermi (HT), yumu\u015fak doku sarkomu, serviks kanseri, tekrarlayan meme kanseri, malign melanom, rektum kanseri, mesane kanseri ve ba\u015f-boyun t\u00fcm\u00f6rleri (HNC) gibi \u00f6nemli onkolojik endikasyonlar i\u00e7in *D\u00fczey 1A kan\u0131tlar\u0131na* (rastgele Faz III \u00e7al\u0131\u015fmalar\u0131 ve meta-analizlere dayanarak) sahip kan\u0131tlanm\u0131\u015f bir tedavidir.<\/p>\n<h3>S: Hipertermi i\u00e7in optimal \u00e7al\u0131\u015fma s\u0131cakl\u0131\u011f\u0131 nedir?<\/h3>\n<p>*C:* Optimal \u00e7al\u0131\u015fma s\u0131cakl\u0131\u011f\u0131 *39\u00b0C ile 45\u00b0C* aras\u0131ndad\u0131r. Bu &#8220;terap\u00f6tik pencere&#8221;, do\u011frudan y\u0131k\u0131m\u0131 (ablasyon) hedeflemez, ancak kanser h\u00fccrelerinin kemo- ve radyoterapiye biyolojik hassasiyet etkisini maksimize eder.<\/p>\n<h3>S: Hipertermi, kemo- veya radyoterapinin toksisitesini art\u0131r\u0131r m\u0131?<\/h3>\n<p>*C:* Faz III \u00e7al\u0131\u015fmalar\u0131n\u0131n analizi, Hipertermi&#8217;nin eklenmesinin *ciddi sistemik toksisiteyi (grade 3-4) anlaml\u0131 \u00f6l\u00e7\u00fcde art\u0131rmad\u0131\u011f\u0131n\u0131* do\u011frulamaktad\u0131r. HT ile ilgili yan etkiler \u00e7o\u011funlukla lokalizedir ve kolayca y\u00f6netilebilir (\u00f6rne\u011fin, hafif cilt reaksiyonlar\u0131).<\/p>\n<h3>S: Hipertermi, Radyoterapiyi nas\u0131l iyile\u015ftirir?<\/h3>\n<p>*C:* Hipertermi, iki ana mekanizma arac\u0131l\u0131\u011f\u0131yla g\u00fc\u00e7l\u00fc bir radyosensitivizat\u00f6r olarak hareket eder: *1)* Radyasyonun zarar verdi\u011fi DNA onar\u0131m mekanizmalar\u0131n\u0131 engeller ve *2)* T\u00fcm\u00f6r kan ak\u0131\u015f\u0131n\u0131 ve oksijenlenmesini iyile\u015ftirir, bu da daha \u00f6nce diren\u00e7li olan h\u00fccreleri \u0131\u015f\u0131nlamaya \u00e7ok daha duyarl\u0131 hale getirir.<\/p>\n<h3>S: Hangi kanser t\u00fcrleri Hipertermiden en \u00e7ok fayda g\u00f6r\u00fcr?<\/h3>\n<p>*C:* D\u00fczey 1A kan\u0131tlar\u0131na g\u00f6re, *Yumu\u015fak Doku Sarkomu, Serviks Kanseri, Tekrarlayan Meme Kanseri, Malign Melanom, Rektum Kanseri, Mesane Kanseri ve HNC* i\u00e7in sa\u011fkal\u0131m faydalar\u0131 g\u00f6sterilmi\u015ftir.<\/p>\n<p>Al\u0131nt\u0131lar (Al\u0131nt\u0131 metni de\u011fi\u015ftirilmeden kal\u0131r)<br \/>\n1. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/<\/p>\n<p>2. Full article: Systematic review of the registered clinical trials for oncological hyperthermia treatment &#8211; Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2022.2076292<\/p>\n<p>3. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. &#8211; Jefferson Digital Commons, https:\/\/jdc.jefferson.edu\/cgi\/viewcontent.cgi?article=1070&amp;context=radoncfp<\/p>\n<p>4. Full article: Hyperthermia and immunotherapy: clinical opportunities &#8211; Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2019.1653499<\/p>\n<p>5. Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer &#8211; PMC, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11575926\/<\/p>\n<p>6. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive &#8230;, https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/p>\n<p>7. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8994727\/<\/p>\n<p>8. Full article: Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy &#8211; Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2021.2002435<\/p>\n<p>9. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3 &#8211; PubMed Central, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8984886\/<\/p>\n<p>10. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas &#8211; MDPI, https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880<\/p>\n<p>11.Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study, Retrospective study , Author:<\/p>\n<div class=\"entry-content\">\n<div class=\"container\">\n<div class=\"acf-fields \">\n<div class=\"publ-acf acf-row acf-flex\">\n<div class=\"szerzok\"><span class=\"sz-nev\">Fiorentini G<\/span>\u00a0<span class=\"sz-nev\">Sarti D<\/span>\u00a0<span class=\"sz-nev\">Milandri C<\/span>\u00a0<span class=\"sz-nev\">Dentico P<\/span>\u00a0<span class=\"sz-nev\">Mambrini A<\/span>\u00a0<span class=\"sz-nev\">Fiorentini C<\/span>\u00a0<span class=\"sz-nev\">Mattioli G<\/span>\u00a0<span class=\"sz-nev\">Casadei<\/span>\u00a0<span class=\"sz-nev\">Guadagni S<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>12. Current understanding of modulated electro-hyperthermia in cancer treatment -; Kosin Medical Journal, https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294<br \/>\n13.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yetki ve Uzmanl\u0131k (E-E-A-T): Dr. Veronica Iatan, MD, ve Cristian Gologan M.Sc, Andromedichyperthermia Modern Onkolojide Hiperterminin Terap\u00f6tik Entegrasyonu: Faz III \u00c7al\u0131\u015fmalar\u0131n\u0131n ve Meta-Analizlerin Ele\u015ftirel Bir Analizi (OS, DFS, CR U\u00e7 Noktalar\u0131) 1. Y\u00f6netici \u00d6zeti ve Hipertermi&#8217;nin Temel Prensipleri (HT) *Onkolojik Hipertermi (HT), kontroll\u00fc olarak **39\u00b0C ile 45\u00b0C* aras\u0131ndaki s\u0131cakl\u0131k aral\u0131\u011f\u0131nda \u0131s\u0131 uygulanmas\u0131 olarak tan\u0131mlan\u0131r ve&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[197,1031,32],"tags":[305,306,307],"class_list":["post-11174","post","type-post","status-publish","format-standard","hentry","category-news-tr","category-studii-clinice-tr","category-uncategorized-tr","tag-faz-iii-calismalarinin","tag-hipertermi","tag-meta-analizlerin"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/11174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/comments?post=11174"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/11174\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media?parent=11174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/categories?post=11174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/tags?post=11174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}